EPA-E Composition for Cardiovascular Event Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular events, such as HMG-CoA reductase inhibitor therapy, are insufficient in preventing the onset and recurrence of cardiovascular events, particularly in patients who have undergone cardiovascular angioplasty and are in the unstable period following the procedure.
Innovation Solution
A composition and method utilizing ethyl icosapentate (EPA-E) as a primary component, administered orally in high purity, either alone or in combination with HMG-CoA reductase inhibitors, to prevent cardiovascular events in hyperlipidemia patients and those who have experienced acute myocardial infarction or cardiovascular angioplasty, with a focus on long-term administration beyond six months post-procedure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HMG-CoA reductase inhibitor therapy is used to treat hyperlipidemia, then serum cholesterol and triglyceride levels are reduced, but the incidence rate of cardiovascular events is not sufficiently prevented
Solution Approach 1:
The patent combines HMG-CoA reductase inhibitors with EPA ethyl ester to create a composite therapy regimen. This merging of two different therapeutic approaches (statin therapy and omega-3 fatty acid supplementation) produces a synergistic effect that reduces cardiovascular events more effectively than either treatment alone, directly addressing the insufficiency of monotherapy
2Reliability
If high purity EPA ethyl ester is administered to patients, then the incidence rate of cardiovascular events is reduced by 19-33%, but the composition requires high purity standards to minimize impurities and oxidative instability
Solution Approach 1:
The patent extracts and isolates EPA ethyl ester from fish oil through a purification process that removes impurities and oxidative contaminants. This extraction and purification approach ensures high purity standards (96% or higher) are achieved, enabling the therapeutic benefits of EPA while eliminating harmful impurities that would otherwise limit its use
3Reliability
If EPA ethyl ester is used in combination with HMG-CoA reductase inhibitors, then cardiovascular event prevention is enhanced, but the treatment regimen becomes more complex
Solution Approach 1:
The patent segments the treatment into distinct components with specific dosing guidelines: HMG-CoA reductase inhibitors at standardized doses and EPA ethyl ester at 1.8-4.0 g/day. This segmentation allows each component to be optimized independently while maintaining overall regimen simplicity through clear dosing recommendations and monitoring parameters
Data Source
AI summary
Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.